Real-world Clinical Outcomes with Eculizumab and Ravulizumab in Anti-aquaporin-4 Antibody-positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD): Results from the Global NMO SPOTLIGHT Registry (S6.009)

Elias Sotirchos; Ahmed Obeidat; Ho Jin Kim; Jin Nakahara; Verónica Tkachuk; Lindsey Przybyl; Sami Fam

doi:10.1212/wnl.0000000000216340

June 9, 2026Neurology

Real-world Clinical Outcomes with Eculizumab and Ravulizumab in Anti-aquaporin-4 Antibody-positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD): Results from the Global NMO SPOTLIGHT Registry (S6.009)

View Full Paper

Ask AI

Bookmark

Share

Key Points

The aim is to analyze the characteristics and clinical outcomes of patients with AQP4-Ab+ NMOSD treated with complement component 5 inhibitors.
Data collected from the Global NMO SPOTLIGHT Registry
Patients received either eculizumab or ravulizumab
Evaluated clinical outcomes including symptom improvement
Patients showed improved clinical outcomes after treatment with eculizumab and ravulizumab
Details on specific outcome metrics from registry data indicate favorable responses
Comparative effectiveness of both therapies observed among patients

Implication

Registry data reveals clinical outcomes in AQP4-Ab+ NMOSD patients treated with C5 inhibitors, suggesting effective management strategies.

Abstract

Describe the characteristics and clinical outcomes of patients with AQP4-Ab+ NMOSD treated with Alexion complement component 5 inhibitor therapies (ALXN-C5ITs, eculizumab and ravulizumab).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sotirchos et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf3b4faef96ed7f05630d https://doi.org/10.1212/wnl.0000000000216340

View Full Paper

Ask AI

Bookmark

Share

Real-world Clinical Outcomes with Eculizumab and Ravulizumab in Anti-aquaporin-4 Antibody-positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD): Results from the Global NMO SPOTLIGHT Registry (S6.009)

Key Points

Implication

Abstract

Discussion

Cite This Study

Real-world Clinical Outcomes with Eculizumab and Ravulizumab in Anti-aquaporin-4 Antibody-positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD): Results from the Global NMO SPOTLIGHT Registry (S6.009)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading